Tolero Pharmaceuticals To Present Positive Advancement Of Clinical And Preclinical Programs At The American Association for Cancer Research 2015

SALT LAKE CITY, Utah--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, announced today that Tolero and collaborators will present seven poster presentations scheduled at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, Pennsylvania, April 18-22, 2015. The presentations include clinical proof-of-concept data for alvocidib, a Phase III-ready CDK9 inhibitor for acute myeloid leukemia, as well as preclinical data for four of Tolero’s pipeline programs.

Help employers find you! Check out all the jobs and post your resume.